Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2004 Dec;59(12):1081–1088. doi: 10.1136/thx.2004.030551

Inflammatory response associated with pulmonary complications in non-HIV immunocompromised patients

C Agusti 1, A Rano 1, M Rovira 1, X Filella 1, N Benito 1, A Moreno 1, A Torres 1
PMCID: PMC1746894  PMID: 15563709

Abstract

Background: A study was undertaken to evaluate the local and systemic inflammatory response associated with pulmonary complications in immunocompromised patients and potential implications regarding severity and prognosis.

Methods: Levels of different inflammatory mediators were measured in the bronchoalveolar lavage (BAL) fluid and serum on days 1 and 4 after the identification of the pulmonary complication in 127 patients with different immunosuppressive conditions.

Results: Pulmonary complications were characterised by a high percentage of neutrophils and increased levels of tumour necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 and IL-10 in the BAL fluid and high serum levels of TNF-α, IL-6, and plasma C-reactive protein (CRP). The inflammatory response was similar in the different groups of immunocompromised patients evaluated. The levels of proinflammatory cytokines were higher in patients with pulmonary infections, particularly those of bacterial aetiology. Patients with a more severe pulmonary infection had a more intense local and systemic inflammatory response. A BAL fluid IL-6 level of >40 pg/ml was an independent predictor of mortality (OR 4.65, 95% CI 1.3 to 16.1), together with a need for mechanical ventilation (OR 13.5, 95% CI 3.2 to 57.3). Patients who died had persistently high levels of CRP on day 4.

Conclusions: The evaluation of the inflammatory response, particularly the determination of IL-6 levels in the BAL fluid and CRP in the serum, may be useful for deciding the appropriate management of pulmonary complications in immunocompromised patients.

Full Text

The Full Text of this article is available as a PDF (125.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agustí Carlos, Rañ Ana, Filella Xavier, González Juliá, Moreno Asunción, Xaubet Antoni, Torres Antoni. Pulmonary infiltrates in patients receiving long-term glucocorticoid treatment: etiology, prognostic factors, and associated inflammatory response. Chest. 2003 Feb;123(2):488–498. doi: 10.1378/chest.123.2.488. [DOI] [PubMed] [Google Scholar]
  2. Agustí Carlos, Torres Antoni. Dying from pneumonia: what gene is the culprit? Crit Care Med. 2004 May;32(5):1225–1226. doi: 10.1097/01.ccm.0000125514.55367.23. [DOI] [PubMed] [Google Scholar]
  3. Angrill J., Agustí C., De Celis R., Filella X., Rañ A., Elena M., De La Bellacasa J. P., Xaubet A., Torres A. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med. 2001 Nov 1;164(9):1628–1632. doi: 10.1164/ajrccm.164.9.2105083. [DOI] [PubMed] [Google Scholar]
  4. Antunes G., Evans S. A., Lordan J. L., Frew A. J. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002 Oct;20(4):990–995. doi: 10.1183/09031936.02.00295102. [DOI] [PubMed] [Google Scholar]
  5. Bauer T. T., Montón C., Torres A., Cabello H., Fillela X., Maldonado A., Nicolás J. M., Zavala E. Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax. 2000 Jan;55(1):46–52. doi: 10.1136/thorax.55.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bonfield T. L., Panuska J. R., Konstan M. W., Hilliard K. A., Hilliard J. B., Ghnaim H., Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med. 1995 Dec;152(6 Pt 1):2111–2118. doi: 10.1164/ajrccm.152.6.8520783. [DOI] [PubMed] [Google Scholar]
  7. Bonten M. J., Froon A. H., Gaillard C. A., Greve J. W., de Leeuw P. W., Drent M., Stobberingh E. E., Buurman W. A. The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1105–1113. doi: 10.1164/ajrccm.156.4.9610002. [DOI] [PubMed] [Google Scholar]
  8. Dehoux M. S., Boutten A., Ostinelli J., Seta N., Dombret M. C., Crestani B., Deschenes M., Trouillet J. L., Aubier M. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 1994 Sep;150(3):710–716. doi: 10.1164/ajrccm.150.3.8087341. [DOI] [PubMed] [Google Scholar]
  9. Glynn P., Coakley R., Kilgallen I., Murphy N., O'Neill S. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax. 1999 Jan;54(1):51–55. doi: 10.1136/thx.54.1.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Groeneveld A. B. J., Tacx A. N., Bossink A. W. J., van Mierlo G. J., Hack C. E. Circulating inflammatory mediators predict shock and mortality in febrile patients with microbial infection. Clin Immunol. 2003 Feb;106(2):106–115. doi: 10.1016/s1521-6616(02)00025-6. [DOI] [PubMed] [Google Scholar]
  11. Jagger M. P., Huo Z., Riches P. G. Inflammatory cytokine (interleukin 6 and tumour necrosis factor alpha) release in a human whole blood system in response to Streptococcus pneumoniae serotype 14 and its capsular polysaccharide. Clin Exp Immunol. 2002 Dec;130(3):467–474. doi: 10.1046/j.1365-2249.2002.01946.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Knaus W. A., Draper E. A., Wagner D. P., Zimmerman J. E. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818–829. [PubMed] [Google Scholar]
  13. Kragsbjerg P., Holmberg H., Vikerfors T. Dynamics of blood cytokine concentrations in patients with bacteremic infections. Scand J Infect Dis. 1996;28(4):391–398. doi: 10.3109/00365549609037926. [DOI] [PubMed] [Google Scholar]
  14. Lien Egil, Ingalls Robin R. Toll-like receptors. Crit Care Med. 2002 Jan;30(1 Suppl):S1–11. [PubMed] [Google Scholar]
  15. Min C. K., Lee W. Y., Min D. J., Lee D. G., Kim Y. J., Park Y. H., Kim H. J., Lee S., Kim D. W., Lee J. W. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 Nov;28(10):935–940. doi: 10.1038/sj.bmt.1703258. [DOI] [PubMed] [Google Scholar]
  16. Montón C., Torres A., El-Ebiary M., Filella X., Xaubet A., de la Bellacasa J. P. Cytokine expression in severe pneumonia: a bronchoalveolar lavage study. Crit Care Med. 1999 Sep;27(9):1745–1753. doi: 10.1097/00003246-199909000-00008. [DOI] [PubMed] [Google Scholar]
  17. Nelson S., Mason C. M., Kolls J., Summer W. R. Pathophysiology of pneumonia. Clin Chest Med. 1995 Mar;16(1):1–12. [PubMed] [Google Scholar]
  18. Oberholzer Andreas, Oberholzer Caroline, Moldawer Lyle L. Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug. Crit Care Med. 2002 Jan;30(1 Suppl):S58–S63. [PubMed] [Google Scholar]
  19. Poe R. H., Wahl G. W., Qazi R., Kallay M. C., Utell M. J., Morrow G. R. Predictors of mortality in the immunocompromised patient with pulmonary infiltrates. Arch Intern Med. 1986 Jul;146(7):1304–1308. [PubMed] [Google Scholar]
  20. Ranieri V. M., Suter P. M., Tortorella C., De Tullio R., Dayer J. M., Brienza A., Bruno F., Slutsky A. S. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1999 Jul 7;282(1):54–61. doi: 10.1001/jama.282.1.54. [DOI] [PubMed] [Google Scholar]
  21. Rañ A., Agustí C., Jimenez P., Angrill J., Benito N., Danés C., González J., Rovira M., Pumarola T., Moreno A. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures. Thorax. 2001 May;56(5):379–387. doi: 10.1136/thorax.56.5.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rañ Ana, Agustí Carlos, Benito Natividad, Rovira Montserrat, Angrill Joaquim, Pumarola Tomás, Torres Antoni. Prognostic factors of non-HIV immunocompromised patients with pulmonary infiltrates. Chest. 2002 Jul;122(1):253–261. doi: 10.1378/chest.122.1.253. [DOI] [PubMed] [Google Scholar]
  23. Smith R. P., Lipworth B. J., Cree I. A., Spiers E. M., Winter J. H. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest. 1995 Nov;108(5):1288–1291. doi: 10.1378/chest.108.5.1288. [DOI] [PubMed] [Google Scholar]
  24. Taniguchi T., Koido Y., Aiboshi J., Yamashita T., Suzaki S., Kurokawa A. Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med. 1999 Jul;27(7):1262–1264. doi: 10.1097/00003246-199907000-00005. [DOI] [PubMed] [Google Scholar]
  25. Toikka P., Irjala K., Juvén T., Virkki R., Mertsola J., Leinonen M., Ruuskanen O. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J. 2000 Jul;19(7):598–602. doi: 10.1097/00006454-200007000-00003. [DOI] [PubMed] [Google Scholar]
  26. Tuomanen E. I., Austrian R., Masure H. R. Pathogenesis of pneumococcal infection. N Engl J Med. 1995 May 11;332(19):1280–1284. doi: 10.1056/NEJM199505113321907. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES